Alkasar 18

Drug Profile

Alkasar 18

Alternative Names: N4-octadecyl-ara-C; NOAC

Latest Information Update: 03 Apr 2007

Price : $50

At a glance

  • Originator University Hospital Zurich
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 01 Jun 2000 Phase-I/II clinical trials in Cancer in Switzerland (unspecified route)
  • 14 Dec 1999 A study has been added to the pharmacokinetics section
  • 18 Dec 1997 A preclinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top